{"url_path":"/sec/tovx/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-093782-index.html","accession_number":"0001104659-26-093782","cik":"0000894158","ticker":"TOVX","issuer_name":"Theriva Biologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-093782-index.html","primary_entity_key":"0000894158","primary_entity_name":"Theriva Biologics, Inc."},"word_count":89,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits**\n\n \n\n(d)  \nExhibits.\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n[99.1](tm2622636d1_ex99-1.htm)\n \n[Press Release issued by Theriva Biologics, Inc., dated August 11, 2026.](tm2622636d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\nDated: August 11, 2026\n**THERIVA BIOLOGICS, INC.**\n\n \n \n \n \n\n \nBy:\n/s/ Steven A. Shallcross\n\n \n \nName:\nSteven A. Shallcross\n\n \n \nTitle:\nChief Executive Officer and Chief Financial\nOfficer"}